## Yong-Bok Lee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2776602/publications.pdf

Version: 2024-02-01

279798 243625 2,229 103 23 44 citations h-index g-index papers 103 103 103 3099 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. European Journal of Pharmaceutical Sciences, 2003, 18, 165-173.	4.0	224
2	Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. International Journal of Pharmaceutics, 2009, 374, 66-72.	5.2	222
3	The effects of mixed MPEG–PLA/Pluronic® copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials, 2010, 31, 2371-2379.	11.4	171
4	Physicochemical characterization of poly(l-lactic acid) and poly(d,l-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier. International Journal of Pharmaceutics, 2005, 298, 255-262.	5.2	115
5	Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 164-171.	4.3	79
6	Release of adriamycin from poly( $\hat{I}^3$ -benzyl-l-glutamate)/poly(ethylene oxide) nanoparticles. International Journal of Pharmaceutics, 1999, 181, 107-115.	5 <b>.</b> 2	73
7	Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. Food and Chemical Toxicology, 2016, 97, 243-255.	3.6	72
8	Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects. AAPS Journal, 2013, 15, 571-580.	4.4	66
9	Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. International Journal of Pharmaceutics, 1998, 175, 17-24.	5.2	53
10	Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery. International Journal of Molecular Sciences, 2019, 20, 3312.	4.1	53
11	Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and <i>ABCB1</i> . British Journal of Clinical Pharmacology, 2010, 69, 27-37.	2.4	43
12	Spectroscopic characterization of ibuprofen/2-hydroxypropyl- $\hat{l}^2$ -cyclodextrin inclusion complex. International Journal of Pharmaceutics, 1998, 175, 215-223.	5.2	42
13	Influence of <i>ABCB1</i> genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with <i>CYP2D6</i> * <i>10</i> /i>/i* <i>10</i> /i>. British Journal of Pharmacology, 2011, 164, 433-443.	5 <b>.</b> 4	41
14	Scrub Typhus Meningitis or Meningoencephalitis. American Journal of Tropical Medicine and Hygiene, 2013, 89, 1206-1211.	1.4	40
15	Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: Physicochemical characterization and pharmacokinetics in beagle dogs. International Journal of Pharmaceutics, 2010, 397, 225-230.	5 <b>.</b> 2	37
16	Characteristics of levan fructotransferase from Arthrobacter ureafaciens K2032 and difructose anhydride IV formation from levan. Enzyme and Microbial Technology, 2000, 27, 212-218.	3.2	36
17	Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. Pharmaceutics, 2019, 11, 168.	4.5	36
18	Hydrophilic interaction liquid chromatography–tandem mass spectrometry for the determination of levosulpiride in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 345-350.	2.3	35

#	Article	IF	Citations
19	Exploring sex differences in human health risk assessment for PFNA and PFDA using a PBPK model. Archives of Toxicology, 2019, 93, 311-330.	4.2	28
20	Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. Pharmaceutics, 2020, 12, 978.	4.5	28
21	Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate. Archives of Toxicology, 2020, 94, 2377-2400.	4.2	26
22	Preparation and Evaluation of Solid-Self-Emulsifying Drug Delivery System Containing Paclitaxel for Lymphatic Delivery. Journal of Nanomaterials, 2016, 2016, 1-14.	2.7	25
23	Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 329-341.	1.8	24
24	Simultaneous determination of puerarin and its active metabolite in human plasma by UPLC-MS/MS: Application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 971, 64-71.	2.3	24
25	Nano-Sized Drug Delivery Systems for Lymphatic Delivery. Journal of Nanoscience and Nanotechnology, 2014, 14, 868-880.	0.9	23
26	Preparation and characterization of cytarabine-loaded $w/o/w$ multiple emulsions. International Journal of Pharmaceutics, 1995, 124, 61-67.	5.2	22
27	Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model. Archives of Toxicology, 2018, 92, 1113-1131.	4.2	22
28	Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery. Archives of Pharmacal Research, 2018, 41, 797-814.	6.3	22
29	High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma. Biomedical Applications, 1999, 723, 239-246.	1.7	20
30	Preparation and in Vivo Evaluation of Piroxicam-Loaded Gelatin Microcapsule by Spray Drying Technique. Biological and Pharmaceutical Bulletin, 2008, 31, 1284-1287.	1.4	20
31	Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience, 2010, 169, 378-387.	2.3	19
32	Scrub typhus meningoencephalitis occurring during doxycycline therapy for Orientia tsutsugamushi. Diagnostic Microbiology and Infectious Disease, 2011, 69, 271-274.	1.8	19
33	Self-Emulsifying Drug Delivery System for Enhancing Bioavailability and Lymphatic Delivery of Tacrolimus. Journal of Nanoscience and Nanotechnology, 2015, 15, 1831-1841.	0.9	17
34	Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. Archives of Pharmacal Research, 2011, 34, 1817-1828.	6.3	16
35	Gender differences in pharmacokinetics and tissue distribution of 4-n-nonylphenol in rats. Archives of Toxicology, 2019, 93, 3121-3139.	4.2	16
36	Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. European Journal of Clinical Pharmacology, 2011, 67, 889-898.	1.9	15

#	Article	IF	Citations
37	Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 798, 257-264.	2.3	13
38	Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1095, 214-225.	2.3	13
39	A sensitive UPLC–ESI–MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma. Journal of Pharmaceutical Investigation, 2020, 50, 159-172.	5.3	13
40	Oral delivery of topotecan in polymeric nanoparticles: Lymphatic distribution and pharmacokinetics. Journal of Controlled Release, 2021, 335, 86-102.	9.9	13
41	Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects. Pharmaceutics, 2021, 13, 754.	4.5	12
42	The Effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Archives of Pharmacal Research, 2007, 30, 96-101.	6.3	11
43	Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: A randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. Clinical Therapeutics, 2009, 31, 2712-2721.	2.5	11
44	Preparation and Evaluation of PEGylated and Folate-PEGylated Liposomes Containing Paclitaxel for Lymphatic Delivery. Journal of Nanomaterials, 2015, 2015, 1-10.	2.7	11
45	Simultaneous determination of imperatorin and its metabolite xanthotoxol in rat plasma and urine by LC–MS/MS and its application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1044-1045, 30-38.	2.3	11
46	Simultaneous Determination of Decursin, Decursinol Angelate, Nodakenin, and Decursinol of Angelica gigas Nakai in Human Plasma by UHPLC-MS/MS: Application to Pharmacokinetic Study. Molecules, 2018, 23, 1019.	3.8	11
47	Determination of tiropramide in human plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 395-400.	2.3	10
48	Evaluation of PEG-Transferrin-PEI Nanocomplex as a Gene Delivery Agent. Journal of Nanoscience and Nanotechnology, 2011, 11, 7078-7081.	0.9	10
49	Simultaneous determination of diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 173, 108-119.	2.8	10
50	Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism. Journal of Pharmaceutical Investigation, 2022, 52, 109-127.	5.3	10
51	Enhanced dissolution rates of piroxicam from the ground mixtures with chitin or chitosan. Archives of Pharmacal Research, 1986, 9, 55-61.	6.3	9
52	Immobilization of levan fructotransferase for the production of di-fructose anhydride from levan. Biotechnology Letters, 2001, 23, 1335-1339.	2.2	9
53	Preparation and mucoadhesive test of CSA-loaded liposomes with different characteristics for the intestinal lymphatic delivery. Biotechnology and Bioprocess Engineering, 2005, 10, 516-521.	2.6	9
54	A sensitive UHPLC–MS/MS method for the simultaneous quantification of three lignans in human plasma and its application to a pharmacokinetic study. Journal of Separation Science, 2017, 40, 3430-3439.	2.5	9

#	Article	IF	Citations
55	Comparison of UPLC-MS/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma. Journal of Pharmaceutical Investigation, 2019, 49, 613-624.	5.3	9
56	Simultaneous determination of three iridoid glycosides of Rehmannia glutinosa in rat biological samples using a validated hydrophilic interaction–UHPLC–MS/MS method in pharmacokinetic and in vitro studies. Journal of Separation Science, 2020, 43, 4148-4161.	2.5	9
57	Banhahubak-Tang Tablet, a Standardized Medicine Attenuates Allergic Asthma via Inhibition of Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 6 (STAT6) Signal Pathway. Molecules, 2020, 25, 2206.	3.8	9
58	Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects. Pharmaceutics, 2020, 12, 374.	4.5	9
59	Sensitive liquid chromatography-tandem mass spectrometry method for the simultaneous determination of benzyl butyl phthalate and its metabolites, monobenzyl phthalate and monobutyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study. Analytical and Bioanalytical Chemistry. 2015. 407. 7391-7400.	3.7	8
60	Development of new clean-up method for UPLC–MS/MS analysis of leuprolide. Journal of Pharmaceutical Investigation, 2017, 47, 531-540.	5 <b>.</b> 3	8
61	Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans. Pharmaceutics, 2019, 11, 531.	4.5	8
62	Toxicokinetics of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rats: UPLC-ESI-MS/MS method development for the simultaneous determination of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rat plasma, urine, feces, and 11 various tissues collected from a toxicokinetic study. Food and Chemical Toxicology, 2020, 145, 111747.	3.6	8
63	Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study. Journal of Pharmaceutical Analysis, 2021, 11, 444-457.	5.3	8
64	Human risk assessment of di-isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di-isobutyl phthalate and its major metabolite mono-isobutyl phthalate. Archives of Toxicology, 2021, 95, 2385-2402.	4.2	8
65	Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms. Pharmaceutics, 2022, 14, 771.	4.5	8
66	Controlled release of cyclosporin A from liposomes-in-microspheres as an oral delivery system. Biotechnology and Bioprocess Engineering, 2006, 11, 526-529.	2.6	7
67	Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by highâ€performance liquid chromatography in stability and pharmacokinetic studies. Biomedical Chromatography, 2013, 27, 1438-1443.	1.7	7
68	Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 291-303.	1.8	7
69	Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach. Pharmaceutics, 2021, 13, 1050.	4.5	7
70	Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 567-579.	1.8	6
71	Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. Molecules, 2018, 23, 909.	3.8	6
72	Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats. Chemosphere, 2022, 286, 131706.	8.2	6

#	Article	IF	CITATIONS
73	Biodistribution and genotoxicity of transferrin-conjugated liposomes/DNA complexes in mice. Macromolecular Research, 2005, 13, 218-222.	2.4	5
74	Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 834, 84-92.	2.3	5
75	Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats. Pharmaceuticals, 2020, 13, 231.	3.8	5
76	Gender differences in pharmacokinetics of perfluoropentanoic acid using non-linear mixed-effect modeling in rats. Archives of Toxicology, 2020, 94, 1601-1612.	4.2	5
77	Simultaneous determination of asarinin, βâ€eudesmol, and wogonin in rats using ultraperformance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies following administration of standards and Gumiganghwalâ€tang. Biomedical Chromatography, 2021, 35, e5021.	1.7	5
78	Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically based pharmacokinetic (PBPK) modeling: analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population. Archives of Toxicology, 2022, 96, 2687-2715.	4.2	5
79	No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. Archives of Pharmacal Research, 1998, 21, 411-417.	6.3	4
80	Prolonged Release of Tegafur from S/O/W Multiple Emulsion. Drug Development and Industrial Pharmacy, 1998, 24, 889-894.	2.0	4
81	Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. European Journal of Pharmaceutical Sciences, 2018, 118, 154-164.	4.0	4
82	A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits. Molecules, 2020, 25, 663.	3.8	4
83	Bioequivalence of Torad tablet 5Âmg to Torem tablet 5Âmg (torasemide 5Âmg). Journal of Pharmaceutical Investigation, 2013, 43, 153-159.	5.3	3
84	Pharmacokinetic evaluation of paeoniflorin after oral administration of Paeoniae Radix extract powder to healthy Korean subjects using UPLC-MS/MS. Journal of Pharmaceutical Investigation, 2016, 46, 273-282.	<b>5.</b> 3	3
85	Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1126-1127, 121743.	2.3	3
86	Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays. Molecules, 2020, 25, 209.	3.8	3
87	A novel and sensitive UPLC–MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. Biomedical Chromatography, 2019, 33, e4627.	1.7	2
88	Simultaneous measurement of epinastine and its metabolite, 9,13bâ€dehydroepinastine, in human plasma by a newly developed ultraâ€performance liquid chromatography–tandem mass spectrometry and its application to pharmacokinetic studies. Biomedical Chromatography, 2020, 34, e4848.	1.7	2
89	Haplotype Analysis and Single Nucleotide Polymorphism Frequency of Organic Cation Transporter Gene (OCT1 and 2) in Korean Subjects. Journal of Korean Pharmaceutical Sciences, 2009, 39, 345-351.	0.0	2
90	Nano-sized Drug Carriers and Key Factors for Lymphatic Delivery. Journal of Pharmaceutical Investigation, 2010, 40, 75-82.	<b>5.</b> 3	2

#	Article	IF	CITATIONS
91	Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets. International Journal of Clinical Pharmacology and Therapeutics, 2018, 56, 292-300.	0.6	2
92	Pharmacokinetic Profile of Kaurenoic Acid after Oral Administration of Araliae Continentalis Radix Extract Powder to Humans. Pharmaceutics, 2018, 10, 253.	4.5	1
93	Response to Hethey et al., 2019 letter to the editor in archives of toxicology. Archives of Toxicology, 2019, 93, 3033-3035.	4.2	1
94	Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method. Archives of Toxicology, 2021, 95, 3515-3537.	4.2	1
95	Haplotype Analysis and Single Nucleotide Polymorphism Frequency of PEPT1 Gene (Exon 5 and 16) in Korean. Journal of Korean Pharmaceutical Sciences, 2009, 39, 411-416.	0.0	1
96	Determination of ibudilast in human serum by high-performance liquid chromatography for pharmacokinetic study. Biomedical Chromatography, 2009, 24, n/a-n/a.	1.7	0
97	Bioequivalence of Samchundang Berastolin tablet to Jeil Berasil tablet (beraprost sodium 20Âμg). Journal of Pharmaceutical Investigation, 2013, 43, 251-257.	5.3	0
98	Effect of genetic polymorphisms on the interplay of P-glycoprotein transporter and cytochrome P450 enzymes: Pharmacokinetics of risperidone. Asian Journal of Pharmaceutical Sciences, 2016, 11, 31-32.	9.1	0
99	Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma. Journal of Pharmaceutical Analysis, 2020, 11, 351-363.	5.3	0
100	Response to "Translational toxicology of sex specific PFNA clearance in rat and human― Archives of Toxicology, 2020, 94, 649-650.	4.2	0
101	In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching. Journal of Pharmaceutical and Biomedical Analysis, 2021, 196, 113931.	2.8	0
102	Pharmacokinetic Changes According to Single or Multiple Oral Administrations of Socheongryong-Tang to Rats: Presented as a Typical Example of Changes in the Pharmacokinetics Following Multiple Exposures to Herbal Medicines. Pharmaceutics, 2021, 13, 478.	4.5	0
103	Gene Expression Changes Associated with Sustained p16 Expression in Hepatocellular Carcinoma Cells. Immune Network, 2004, 4, 237.	3.6	O